Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (>60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicular lymphoma grade IIIb.

Trial Profile

Phase II, randomised, multicentre study with two treatment arms (R-COMP versus R-CHOP) in newly diagnosed elderly patients (>60 years) with non-localised diffuse large B-cell lymphoma (DLBCL)/follicular lymphoma grade IIIb.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Preliminary results assessing subclinical cardio-toxicity, safety and efficacy presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 02 Sep 2016 Planned primary completion date changed from 1 Feb 2021 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top